JOURNAL OF THROMBOSIS AND THROMBOLYSIS, cilt.18, sa.3, ss.213-216, 2005 (SCI-Expanded)
Backround: Currently, all treatments for patients with myelodysplastic syndrome (MDS) are still experimental. Supportive care, including treatment of infection and transfusion of blood and blood-related products, remains the most important aspect of therapy in these cases. This article discusses the results of partial splenic embolization in a patient who had MDS with refractory anemia.